News 7/16

top of page

Multiple sclerosis News | Tysabri is now available as SC in Europe

Multiple sclerosis News | Tysabri is now available as SC in Europe

Multiple sclerosis News | Tysabri is now available as SC in Europe

ipharmaservices

Apr 9, 2021

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

ipharmaservices

Apr 7, 2021

Is AstraZeneca and Oxford’s COVID vaccine safe? Australia prefers Pfizer vaccine

Is AstraZeneca and Oxford’s COVID vaccine safe? Australia prefers Pfizer vaccine

Is AstraZeneca and Oxford’s COVID vaccine safe? Australia prefers Pfizer vaccine

ipharmaservices

Mar 29, 2021

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

ipharmaservices

Mar 28, 2021

FDA drug approvals| Actemra approved for SSc-ILD | Libtayo for NSCLC

FDA drug approvals| Actemra approved for SSc-ILD | Libtayo for NSCLC

FDA drug approvals| Actemra approved for SSc-ILD | Libtayo for NSCLC

ipharmaservices

Mar 2, 2021

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

ipharmaservices

Feb 21, 2021

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

ipharmaservices

Feb 8, 2021

Merck and Bayer announced the US FDA approval for Verquvo

ipharmaservices

Jan 21, 2021

Expected best selling pharmaceutical products (drugs) in 2021

Expected best selling pharmaceutical products (drugs) in 2021

Expected best selling pharmaceutical products (drugs) in 2021

ipharmaservices

Jan 20, 2021

What Sanofi is expecting to achieve with the acquisition of Kymab?

What Sanofi is expecting to achieve with the acquisition of Kymab?

What Sanofi is expecting to achieve with the acquisition of Kymab?

ipharmaservices

Jan 19, 2021

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

ipharmaservices

Jan 12, 2021

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

ipharmaservices

Jan 12, 2021

Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphoma

ipharmaservices

Dec 28, 2020

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

ipharmaservices

Oct 18, 2020

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

ipharmaservices

Oct 9, 2020

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

ipharmaservices

Oct 3, 2020

Novartis presented data of Zolgensma; Roche presented data of Evrysdi at the World Muscle Society

Novartis presented data of Zolgensma; Roche presented data of Evrysdi at the World Muscle Society

Novartis presented data of Zolgensma; Roche presented data of Evrysdi at the World Muscle Society

ipharmaservices

Oct 3, 2020

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

ipharmaservices

Sep 26, 2020

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

ipharmaservices

Sep 26, 2020

Sanofi and GSK to supply 72 million doses of the COVID-19 vaccine

Sanofi and GSK to supply 72 million doses of the COVID-19 vaccine

Sanofi and GSK to supply 72 million doses of the COVID-19 vaccine

ipharmaservices

Sep 24, 2020

bottom of page